DDInter1429 DDInter1376
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Perflutren {u} (Compound) resembles {v} (Compound) Sevoflurane
Perflutren {u} (Compound) is included by {v} (Pharmacologic Class) Ultrasound Contrast Activity
Perflutren {u} (Compound) causes {v} (Side Effect) Haemoglobin
Perflutren {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Perflutren (Compound) resembles Sevoflurane (Compound)
Perflutren (Compound) is included by Ultrasound Contrast Activity (Pharmacologic Class)
Perflutren (Compound) causes Haemoglobin (Side Effect)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Perflutren may lead to a major life threatening interaction when taken with Cabozantinib
Perflutren may lead to a major life threatening interaction when taken with Anagrelide